News

Morningstar1mon
Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases | Morningstar
New breakthrough data from studies evaluating the vector (research code S01coAAV2) have been selected for presentation as a Late-Breaking Abstract at the 2025 American Society of Gene & Cell ...
Morningstar1mon
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting - Morningstar
SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating ...
The Globe and Mail1mon
Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast Cancer - The Globe and Mail
The Globe and Mail has not reviewed this content. Please see disclaimer . Ludwig Enterprises Announces Publication of ASCO Abstract Detailing Novel Non-Invasive mRNA Signals that Scan for Breast ...
The Globe and Mail2mon
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting - The Globe and Mail
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...